How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 16210286.
- Also identified by PMC identifier 1246089.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recent claims that pioglitazone prevents macrovascular events are based on a secondary outcome measure. But ignoring the primary outcome is statistically unsound
Medical subject headings
- Diabetes Mellitus, Type 2
- Diabetic Angiopathies
- Hypoglycemic Agents
- Thiazolidinediones